This Article  • Full text  • PDF  • Correction  • Correction  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Critical Care/ Intensive Care Medicine  • Adult Critical Care  • Alert me on articles by topic

A Randomized Controlled Trial

The ARDS Network Authors for the ARDS Network

JAMA. 2000;283:1995-2002.

Context  Three clinical studies have suggested that ketoconazole, a synthetic imidazole with anti-inflammatory activity, may prevent the development of acute respiratory distress syndrome (ARDS) in critically ill patients. However, the use of ketoconazole as treatment for acute lung injury (ALI) and ARDS has not been previously studied.

Objective  To test the efficacy of ketoconazole in reducing mortality and morbidity in patients with ALI or ARDS.

Design  Randomized, double-blind, placebo-controlled trial conducted from March 1996 to January 1997.

Setting  Twenty-four hospitals associated with 10 network centers in the United States, constituting the ARDS Network.

Patients  A total of 234 patients with ALI or ARDS.

Intervention  Patients were randomly assigned to receive ketoconazole, 400 mg/d (n=117), or placebo (n=117), initiated within 36 hours of fulfilling study entry criteria and given enterally for up to 21 days.

Main Outcome Measures  Primary outcome measures were the proportion of patients alive with unassisted breathing at hospital discharge and the number of days of unassisted breathing (ventilator-free days) during 28 days of follow-up. Secondary outcome measures included the proportion of patients achieving unassisted breathing for 48 hours or more, the number of organ failure–free days, and changes in plasma interleukin 6 (IL-6) and urinary thromboxane A₂ metabolites (thromboxane B₂ [TXB₂] and 11-dehydro-TXB₂).

Results  In-hospital mortality (SE) was 34.1% (4.3%) for the placebo group and 35.2% (4.3%) for the ketoconazole group (P=.85). The median number of ventilator-free days within 28 days of randomization was 9 in the placebo group and 10 in the ketoconazole group (P=.89). There were no statistically significant differences in the number of organ failure–free days, pulmonary physiology, or adverse events between treatment groups. The median serum ketoconazole level was 1.25 µg/mL and serum levels greater than 0.5 µg/mL were detected in 96% of patients assayed. Plasma IL-6, urinary TXB₂, and 11-dehydro-TXB₂ levels were unaffected by ketoconazole.

Conclusions  In these patients with ALI or ARDS, ketoconazole was safe and bioavailable but did not reduce mortality or duration of mechanical ventilation or improve lung function. These data do not support the use of ketoconazole for the early treatment of ALI or ARDS.

Members of The ARDS Network are listed below. A dagger identifies members who accept and fulfill authorship criteria.

RELATED ARTICLE

April 19, 2000
JAMA. 2000;283(15):2041-2042.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of a Clinical Trial on Mechanical Ventilation Practices in Patients with Acute Lung Injury
Checkley et al.
Am. J. Respir. Crit. Care Med. 2008;177:1215-1222.
ABSTRACT | FULL TEXT  

Mortality Rates for Patients With Acute Lung Injury/ARDS Have Decreased Over Time
Zambon and Vincent
Chest 2008;133:1120-1127.
ABSTRACT | FULL TEXT  

Essential Role of MMP-12 in Fas-Induced Lung Fibrosis
Matute-Bello et al.
Am. J. Respir. Cell Mol. Bio. 2007;37:210-221.
ABSTRACT | FULL TEXT  

Nonventilatory Treatments for Acute Lung Injury and ARDS
Calfee and Matthay
Chest 2007;131:913-920.
ABSTRACT | FULL TEXT  

Posttreatment with Aspirin-Triggered Lipoxin A4 Analog Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice: The Role of Heme Oxygenase-1
Jin et al.
Anesth. Analg. 2007;104:369-377.
ABSTRACT | FULL TEXT  

Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Cepkova and Matthay
J Intensive Care Med 2006;21:119-143.
ABSTRACT  

Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials
Playford et al.
J Antimicrob Chemother 2006;57:628-638.
ABSTRACT | FULL TEXT  

Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit
Parikh et al.
J. Am. Soc. Nephrol. 2005;16:3046-3052.
ABSTRACT | FULL TEXT  

Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury
Fukunaga et al.
J. Immunol. 2005;174:5033-5039.
ABSTRACT | FULL TEXT  

Acute Respiratory Distress Syndrome
Burleson and Maki
Journal of Pharmacy Practice 2005;18:118-131.
ABSTRACT  

Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury
Parsons et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2005;288:L426-L431.
ABSTRACT | FULL TEXT  

Excess Body Weight Is Not Independently Associated with Outcome in Mechanically Ventilated Patients with Acute Lung Injury
O'Brien et al.
ANN INTERN MED 2004;140:338-345.
ABSTRACT | FULL TEXT  

Leukotriene D4 Activates Alveolar Epithelial Na,K-ATPase and Increases Alveolar Fluid Clearance
Sloniewsky et al.
Am. J. Respir. Crit. Care Med. 2004;169:407-412.
ABSTRACT | FULL TEXT  

The Changing Face of Organ Failure in ARDS
Suchyta et al.
Chest 2003;124:1871-1879.
ABSTRACT | FULL TEXT  

Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury
Eisner et al.
Thorax 2003;58:983-988.
ABSTRACT | FULL TEXT  

Inhaled Nitric Oxide for Acute Hypoxic Respiratory Failure in Children and Adults: A Meta-analysis
Sokol et al.
Anesth. Analg. 2003;97:989-998.
ABSTRACT | FULL TEXT  

Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome
Moloney and Evans
Eur Respir J 2003;21:720-727.
ABSTRACT | FULL TEXT  

Nonpeptide Antagonists of AT1 Receptor for Angiotensin II Delay the Onset of Acute Respiratory Distress Syndrome
Raiden et al.
J. Pharmacol. Exp. Ther. 2002;303:45-51.
ABSTRACT | FULL TEXT  

A respiratory gas exchange catheter: In vitro and in vivo tests in large animals
Hattler et al.
J. Thorac. Cardiovasc. Surg. 2002;124:520-530.
ABSTRACT | FULL TEXT  

The pulmonary physician in critical care c 9: Non-ventilatory strategies in ARDS
Cranshaw et al.
Thorax 2002;57:823-829.
ABSTRACT | FULL TEXT  

Recovery Rate and Prognosis in Older Persons Who Develop Acute Lung Injury and the Acute Respiratory Distress Syndrome
Ely et al.
ANN INTERN MED 2002;136:25-36.
ABSTRACT | FULL TEXT  

Clinicians' Approaches to Mechanical Ventilation in Acute Lung Injury and ARDS
Thompson et al.
Chest 2001;120:1622-1627.
ABSTRACT | FULL TEXT  

Treatment of ARDS
Brower et al.
Chest 2001;120:1347-1367.
ABSTRACT | FULL TEXT  

Clinically-oriented therapies in sepsis: a review
Dubois and Vincent
Innate Immunity 2000;6:463-469.
ABSTRACT  

The Acute Respiratory Distress Syndrome
Ware and Matthay
NEJM 2000;342:1334-1349.
FULL TEXT